Research and Clinical Trials

Brief Description  
The purpose of this study is to learn more about the safety, effect and tolerability of 2 different treatment regimens of telaprevir (telaprevir taken every 8 hours per day or telaprevir taken 2 times per day) together with standard treatment pegylated interferon and ribavirin in patients with genotype 1 chronic hepatitis C infection who have not received previous treatment. Telaprevir is an investigational drug for Hepatitis C which targets the Hepatitis C virus and damages its ability to crea
Who may be Eligible  
Adult men and women between 18 and 70 years of age with genotype 1 chronic Hepatitis C infection that have not been previously treated. Subjects may have compensated cirrhosis.
Hepatitis C
IRB Number  
Principal Investigator  
Bonkovsky, Herbert

For More Information, Contact  Gale  W, Groseclose
Phone:  (704) 355-4875  Fax:  (704) 355-9641  
Address:1000 Blythe Boulevard MEB, Ste. 103 Charlotte, NC 28203